155 related articles for article (PubMed ID: 29985537)
41. Krebs von den Lungen-6 (KL-6) as a clinical marker for severe COVID-19: A systematic review and meta-analyses.
Naderi N; Rahimzadeh M
Virology; 2022 Jan; 566():106-113. PubMed ID: 34896901
[TBL] [Abstract][Full Text] [Related]
42. Serum Krebs von den Lungen-6 for Predicting the Severity of COVID-19 Lung Injury: A Systematic Review and Meta-Analysis.
Pramana Witarto A; Samarta Witarto B; Er Putra AJ; Pramudito SL; Rosyid AN
Iran Biomed J; 2021 Nov; 25(6):381-9. PubMed ID: 34641641
[TBL] [Abstract][Full Text] [Related]
43. KL-6 as an Immunological Biomarker Predicts the Severity, Progression, Acute Exacerbation, and Poor Outcomes of Interstitial Lung Disease: A Systematic Review and Meta-Analysis.
Zhang T; Shen P; Duan C; Gao L
Front Immunol; 2021; 12():745233. PubMed ID: 34956179
[TBL] [Abstract][Full Text] [Related]
44. Diagnostic and prognostic predictive values of circulating KL-6 for interstitial lung disease: A PRISMA-compliant systematic review and meta-analysis.
Zhang H; Chen L; Wu L; Huang J; Li H; Wang X; Weng H
Medicine (Baltimore); 2020 Apr; 99(16):e19493. PubMed ID: 32311922
[TBL] [Abstract][Full Text] [Related]
45. Advances in the study of biomarkers of idiopathic pulmonary fibrosis in Japan.
Huang H; Peng X; Nakajima J
Biosci Trends; 2013 Aug; 7(4):172-7. PubMed ID: 24056167
[TBL] [Abstract][Full Text] [Related]
46. Correlation of Krebs von den Lungen-6 and fibronectin with pulmonary fibrosis in coronavirus disease 2019.
Peng DH; Luo Y; Huang LJ; Liao FL; Liu YY; Tang P; Hu HN; Chen W
Clin Chim Acta; 2021 Jun; 517():48-53. PubMed ID: 33631198
[TBL] [Abstract][Full Text] [Related]
47. Could KL-6 levels in COVID-19 help to predict lung disease?
Frix AN; Schoneveld L; Ladang A; Henket M; Duysinx B; Vaillant F; Misset B; Moutschen M; Louis R; Cavalier E; Guiot J
Respir Res; 2020 Nov; 21(1):309. PubMed ID: 33234132
[TBL] [Abstract][Full Text] [Related]
48. Clinical Usefulness of Serum Krebs von den Lungen-6 for Detecting Chronic Aspiration in Children with Severe Motor and Intellectual Disabilities.
Wakamoto H; Sano N; Yano Y; Sakai S; Kikuchi T; Fukuda M; Morimoto T; Ishii E
J Pediatr; 2015 Nov; 167(5):1136-42. PubMed ID: 26382626
[TBL] [Abstract][Full Text] [Related]
49. Interstitial lung disorders in the indium workers of Korea: an update study for the relationship with biological exposure indices.
Choi S; Won YL; Kim D; Lee MY; Choi YJ; Park JS; Kim HR; Jung JI; Lee SG; Kim EA
Am J Ind Med; 2015 Jan; 58(1):61-8. PubMed ID: 25345911
[TBL] [Abstract][Full Text] [Related]
50. Krebs von den Lungen 6 (KL-6) as a marker for disease severity and persistent radiological abnormalities following COVID-19 infection at 12 weeks.
Arnold DT; Donald C; Lyon M; Hamilton FW; Morley AJ; Attwood M; Dipper A; Barratt SL
PLoS One; 2021; 16(4):e0249607. PubMed ID: 33914762
[TBL] [Abstract][Full Text] [Related]
51. Understanding the Utilization of the Krebs von den Lungen 6 Test in a Clinical Laboratory.
Choi R; Lee SG; Lee EH
Clin Lab; 2023 Feb; 69(2):. PubMed ID: 36787568
[TBL] [Abstract][Full Text] [Related]
52. Alteration of serum thymus and activation-regulated chemokine level during biologic therapy for psoriasis: Possibility as a marker reflecting favorable response to anti-interleukin-17A agents.
Shibuya T; Honma M; Iinuma S; Iwasaki T; Takahashi H; Ishida-Yamamoto A
J Dermatol; 2018 Jun; 45(6):710-714. PubMed ID: 29655215
[TBL] [Abstract][Full Text] [Related]
53. Elevation of serum KL-6 glycoprotein or surfactant protein-D in adult T-cell leukemia with distinct pulmonary complications.
Osaka A; Yanagihara K; Yamada Y; Hasegawa H; Inokuchi N; Hayashi T; Komoda M; Nakamura S; Aoyama M; Sawada T; Kamihira S
Tohoku J Exp Med; 2009 Jun; 218(2):99-105. PubMed ID: 19478465
[TBL] [Abstract][Full Text] [Related]
54. Predictive value of serum markers for the development of interstitial lung disease in patients with polymyositis and dermatomyositis: a comparative and prospective study.
Chen F; Lu X; Shu X; Peng Q; Tian X; Wang G
Intern Med J; 2015 Jun; 45(6):641-7. PubMed ID: 25827843
[TBL] [Abstract][Full Text] [Related]
55. Plasma Krebs von den Lungen glycoprotein, lung injury, and noninvasive ventilation in Duchenne muscular dystrophy.
Hamada S; Ishikawa Y; Aoyagi T; Ishikawa Y; Minami R; Bach JR
Am J Phys Med Rehabil; 2012 Oct; 91(10):831-5. PubMed ID: 22760105
[TBL] [Abstract][Full Text] [Related]
56. Elevation of serum KL-6 levels during treatment with tumor necrosis factor-α inhibitor in patients with psoriasis.
Mabuchi T; Yamaoka H; Kawai M; Ota T; Ozawa A
J Dermatol; 2014 Dec; 41(12):1136-7. PubMed ID: 25388751
[No Abstract] [Full Text] [Related]
57. Pneumocyte biomarkers KL-6 and surfactant protein D reflect the distinct findings of high-resolution computed tomography in nonspecific interstitial pneumonia.
Ichiyasu H; Ichikado K; Yamashita A; Iyonaga K; Sakamoto O; Suga M; Kohrogi H
Respiration; 2012; 83(3):190-7. PubMed ID: 21555868
[TBL] [Abstract][Full Text] [Related]
58. Clinical characteristics classified by the serum KL-6 level in patients with organizing pneumonia.
Yamaguchi K; Tsushima K; Kurita N; Fujiwara A; Soeda S; Yamaguchi A; Sugiyama S; Togashi Y; Kono Y; Kasagi S; Setoguchi Y
Sarcoidosis Vasc Diffuse Lung Dis; 2013 Mar; 30(1):43-51. PubMed ID: 24003534
[TBL] [Abstract][Full Text] [Related]
59. Serum Krebs von den Lungen-6 levels are associated with mortality and severity in patients with coronavirus disease 2019.
Yamaya T; Hagiwara E; Baba T; Kitayama T; Murohashi K; Higa K; Sato Y; Otoshi R; Tabata E; Shintani R; Okabayashi H; Ikeda S; Niwa T; Nakazawa A; Oda T; Okuda R; Sekine A; Kitamura H; Komatsu S; Ogura T
Respir Investig; 2021 Sep; 59(5):596-601. PubMed ID: 33965361
[TBL] [Abstract][Full Text] [Related]
60. CA 15-3 as an alternative marker for KL-6 in fibrotic lung diseases.
Kruit A; Gerritsen WB; Pot N; Grutters JC; van den Bosch JM; Ruven HJ
Sarcoidosis Vasc Diffuse Lung Dis; 2010 Jul; 27(2):138-46. PubMed ID: 21319596
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
